InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $3.000 0.82 (37.61%)+
Announcement
Release
19 Feb 2026 8:10AM
Price at Release
$2.180
Full Release
download
Summary
Cogstate Limited reported strong financial results for the first half of fiscal year 2026, ending 31 December 2025, with revenues increasing by 12% to $26.9 million. The revenue growth was primarily driven by a 13% increase in Clinical Trials revenue to $25.7 million. The company executed sales contracts totaling $41.7 million, marking significant progress in diversifying its portfolio to include mood, sleep, and other neurological conditions. EBITDA rose by 5% to $6.5 million, but the EBITDA margin decreased slightly due to increased cost of sales. Despite these costs, the net profit after tax improved by 16% to $4.5 million. Cogstate maintained a strong cash position with $34.1 million at the end of December 2025, reflecting disciplined capital management and strategic investments in AI-powered analytical tools and clinical trial delivery capabilities. The company continues to focus on diversifying revenue streams and expanding its market reach through channel partnerships.
Key Points
  • Revenue increased by 12% to $26.9 million.
  • Clinical Trials revenue rose 13% to $25.7 million.
  • Sales contracts worth $41.7 million were executed.
  • EBITDA increased 5% to $6.5 million, with a margin of 24.3%.
  • Net profit after tax grew 16% to $4.5 million.
  • Strong cash position at $34.1 million with no debt.
  • Investment in AI-powered tools and clinical trial capabilities.
  • Diversification into mood, sleep, and other neurological conditions.
  • Strategic expansion through channel partnerships.
  • Contracted future revenue increased to $104.9 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.